Late-stage focus MaaT Pharma is a clinical-stage biotechnology company targeting microbiome-driven immunomodulation to improve cancer survival, with recent Phase 3 DATA and presentations at major conferences, indicating readiness for partnerships and commercial discussions around advanced therapies.

Strategic partnerships Strong engagement with academic and hospital networks (e.g., EBMT, ASH presentations; collaboration potential with transplant centers and oncology groups) creates opportunities for co-development, enabling trials, or access to patient populations.

Financing momentum Recent € and $ financing from EIB and recognition as Innovative Company signal ongoing funding support, which can be leveraged to discuss co-investment, milestones, and favorable terms for potential licensing or commercial collaborations.

Global visibility Public listing on Euronext Paris and active communications through multiple press and conference channels enhance credibility, aiding outreach to global biopharma partners for co-development, manufacturing, or distribution deals.

Clinical-ready assets ARES/MET pipeline with Phase 3 results for maat013 in acute GvHD demonstrates near-term translational opportunities and potential for strategic alliances in hematology, oncology, and supportive care product lines.